Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NVNO | Common Stock | Options Exercise | +1.04K | +15.74% | 7.66K | Sep 13, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NVNO | Restricted Stock Units | Options Exercise | $0 | -1.04K | -100% | $0.00* | 0 | Sep 13, 2022 | Common Stock | 1.04K | Direct | F1, F2 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation. |
F2 | On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of the RSUs occurred in September 2020, 2021 and 2022. |